In a trial of semaglutide, people who switched to a placebo regained around 7% of their body weight over the following year, while those who kept taking the medication lost a further 8%
Traumatic stress, oxidative stress and post-traumatic stress disorder: neurodegeneration and the accelerated-aging hypothesis
The ESSENCE trial, published in the New England Journal of Medicine in April 2025, provides strong evidence for semaglutide (the drug in Wegovy) in fatty liver disease
The critical point and the one most frequently misunderstood in online discussions is that compounding eligibility is not the same as FDA drug approval
Tirzepatide is currently being tested in another large, cardiovascular outcomes study: SURMOUNT-MMO
Polar and nonpolar lipids from liver tissues were profiled with the use of a Vanquish UHPLC system coupled to an Orbitrap IQ-X mass spectrometer (Thermo Fisher Scientific)